

Ventavis

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: Same as Requ	uesting Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: ☐ Same as Refe	erring Provider 🗆 Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:
accepted compen	o dosing limits in accordance with FDA-approved labeling, ndia, and/or evidence-based practice guidelines.
accepted compenses Required Demographic Information:	ndia, and/or evidence-based practice guidelines.
accepted compension: Required Demographic Information: Patient Weight:	ndia, and/or evidence-based practice guidelineskg
accepted compenses Required Demographic Information:	ndia, and/or evidence-based practice guidelineskg
Required Demographic Information: Patient Weight: Patient Height: Please indicate the place of service for the re	ndia, and/or evidence-based practice guidelineskgcm equested drug:
accepted compensation: Required Demographic Information: Patient Weight: Patient Height: Please indicate the place of service for the re ☐ Ambulatory Surgical	ndia, and/or evidence-based practice guidelines. kgcm equested drug: \$\sigma Off Campus Outpatient Hospital\$
Required Demographic Information: Patient Weight: Patient Height: Please indicate the place of service for the re	ndia, and/or evidence-based practice guidelines. kgcm equested drug: \$\sigma Off Campus Outpatient Hospital\$
accepted compensation: Required Demographic Information: Patient Weight: Patient Height: Please indicate the place of service for the re ☐ Ambulatory Surgical	ndia, and/or evidence-based practice guidelines. kgcm equested drug: \$\sigma Off Campus Outpatient Hospital\$
Required Demographic Information: Patient Weight: Patient Height: Please indicate the place of service for the re Ambulatory Surgical On Campus Outpatient Hospital Drug Information:	ndia, and/or evidence-based practice guidelines. kgcm equested drug: ☐ Home ☐ Off Campus Outpatient Hospital ☐ Office
Required Demographic Information: Patient Weight: Patient Height: Please indicate the place of service for the re Ambulatory Surgical On Campus Outpatient Hospital	kgkgcm equested drug:

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Ventavis SGM 1648-A - 12/2022.

<u>Cri</u> 1.	teria Questions: What is the diagnosis? □ Pulmonary arterial hypertension (PAH) □ Other, please specify		
2.	What is the ICD-10 code?		
3.	Is the requested medication prescribed by or in consultation with a pulmonologist or cardiologist? $\ \square$ Yes $\ \square$ No		
4.	Is the patient currently receiving treatment with the requested medication? \square Yes \square No If No, skip to #7		
5.	Is the patient currently receiving the requested medication through a paid pharmacy or medical benefit? ☐ Yes ☐ No ☐ Unknown If No or Unknown, skip to #7		
6.	Is the patient experiencing benefit from therapy with the requested medication as evidenced by disease stability or disease improvement? \square Yes \square No No further questions		
7.	What is the World Health Organization (WHO) classification of pulmonary hypertension? □ WHO Group 1 (Pulmonary arterial hypertension) □ WHO Group 2 (Pulmonary hypertension owing to left heart disease) □ WHO Group 3 (Pulmonary hypertension owing to lung disease and/or hypoxia) □ WHO Group 4 (Chronic thromboembolic pulmonary hypertension) □ WHO Group 5 (Pulmonary hypertension with unclear multifactorial mechanisms)		
8.	Has the diagnosis been confirmed by right heart catheterization? ☐ Yes ☐ No If No, skip to #12		
9.	What is the pretreatment mean pulmonary arterial pressure (mPAP) at rest? mmHg		
10.	What is the pretreatment pulmonary capillary wedge pressure (PCWP)? mmHg		
11.	What is the pretreatment pulmonary vascular resistance (PVR)? Wood units No further questions		
12.	Is the patient an infant less than one year of age? ☐ Yes ☐ No		
13.	Has Doppler echocardiogram been performed to confirm the diagnosis? ☐ Yes ☐ No		
	test that this information is accurate and true, and that documentation supporting this ormation is available for review if requested by Priority Partners.		

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Ventavis SGM 1648-A – 12/2022.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Prescriber or Authorized Signature